Berenberg Bank Forecasts Strong Price Appreciation for Hikma Pharmaceuticals (LON:HIK) Stock

Key Points

• Berenberg Bank raised Hikma Pharmaceuticals’ price target from GBX 1,800 to GBX 2,100 while maintaining a “buy” rating, implying 29.41% potential upside.
• Analyst sentiment remains strongly positive: six analysts rate the stock “Buy,” with a consensus price target of GBX 2,098.
• Hikma shares opened at GBX 1,622.71, while insider Tobias Hestler purchased 7,500 shares for £123,600; insiders collectively own 22.04% of the company.

Hikma Pharmaceuticals (LON:HIK - Get Free Report) had its target price lifted by Berenberg Bank from GBX 1,800 to GBX 2,100 in a note issued to investors on Tuesday,Digital Look reports. The brokerage currently has a "buy" rating on the stock. Berenberg Bank's target price would suggest a potential upside of 29.41% from the company's current price.

Other equities analysts have also recently issued reports about the company. Jefferies Financial Group lifted their price target on Hikma Pharmaceuticals from GBX 1,850 to GBX 1,870 and gave the company a "buy" rating in a research report on Tuesday, May 5th. Citigroup reaffirmed a "buy" rating on shares of Hikma Pharmaceuticals in a research note on Thursday, July 16th. Finally, Deutsche Bank Aktiengesellschaft reaffirmed a "buy" rating and set a GBX 1,950 target price on shares of Hikma Pharmaceuticals in a report on Friday. Six investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus price target of GBX 2,098.

Hikma Pharmaceuticals Price Performance

LON HIK opened at GBX 1,622.71 on Tuesday. Hikma Pharmaceuticals has a 12 month low of GBX 1,187 and a 12 month high of GBX 1,865. The firm has a market capitalization of £3.39 billion, a PE ratio of 8.97, a P/E/G ratio of 2.38 and a beta of 0.66. The company's 50 day simple moving average is GBX 1,538.45 and its 200 day simple moving average is GBX 1,453.55. The company has a debt-to-equity ratio of 77.57, a current ratio of 1.98 and a quick ratio of 1.27.

Insider Buying and Selling

In other news, insider Tobias Hestler bought 7,500 shares of the firm's stock in a transaction on Monday, August 10th. The stock was bought at an average cost of GBX 1,648 per share, for a total transaction of £123,600. Corporate insiders own 22.04% of the company's stock.

Hikma Pharmaceuticals Company Profile

At Hikma we help put better health within reach, every day. By creating high-quality medicines and making them accessible to the people who need them, we help to shape a healthier world that enriches all our communities. We help deliver this by living our culture, delivering our strategy, and acting responsibly. We are a trusted, reliable partner and dependable source of over 820+ (as of Feb 2026) high-quality generic, specialty and branded pharmaceutical products that hospitals, physicians and pharmacists need to treat their patients across North America, MENA and Europe.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source